Blueprint Medicines Corporation (BPMC): Price and Financial Metrics

Blueprint Medicines Corporation (BPMC): $72.42

0.89 (-1.21%)

POWR Rating

Component Grades








Add BPMC to Watchlist
Sign Up

Industry: Biotech




#265 of 347

in industry

BPMC Price/Volume Stats

Current price $72.42 52-week high $74.00
Prev. close $73.31 52-week low $37.82
Day low $70.89 Volume 777,700
Day high $73.95 Avg. volume 629,751
50-day MA $57.22 Dividend yield N/A
200-day MA $53.35 Market Cap 4.40B

BPMC Stock Price Chart Interactive Chart >


  • Growth is the dimension where BPMC ranks best; there it ranks ahead of 58.28% of US stocks.
  • BPMC's strongest trending metric is Quality; it's been moving down over the last 177 days.
  • BPMC's current lowest rank is in the Stability metric (where it is better than 6.56% of US stocks).

BPMC Stock Summary

  • With a price/sales ratio of 20.26, BLUEPRINT MEDICINES CORP has a higher such ratio than 94.41% of stocks in our set.
  • With a year-over-year growth in debt of 36.92%, BLUEPRINT MEDICINES CORP's debt growth rate surpasses 83.66% of about US stocks.
  • As for revenue growth, note that BPMC's revenue has grown -20.59% over the past 12 months; that beats the revenue growth of merely 13.7% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to BLUEPRINT MEDICINES CORP, a group of peers worth examining would be DCPH, FULC, ADAP, SPCE, and ADVM.
  • Visit BPMC's SEC page to see the company's official filings. To visit the company's web site, go to

BPMC Valuation Summary

  • In comparison to the median Healthcare stock, BPMC's price/sales ratio is 900% higher, now standing at 18.5.
  • Over the past 104 months, BPMC's EV/EBIT ratio has gone up 2.7.

Below are key valuation metrics over time for BPMC.

Stock Date P/S P/B P/E EV/EBIT
BPMC 2023-11-20 18.5 19.8 -7.2 -8.1
BPMC 2023-11-17 17.9 19.1 -7.0 -7.8
BPMC 2023-11-16 17.6 18.8 -6.9 -7.7
BPMC 2023-11-15 17.9 19.1 -7.0 -7.8
BPMC 2023-11-14 18.2 19.4 -7.1 -7.9
BPMC 2023-11-13 16.5 17.7 -6.5 -7.3

BPMC Growth Metrics

    The 2 year price growth rate now stands at 6.53%.
  • The 4 year cash and equivalents growth rate now stands at 560.04%.
  • Its 2 year net income to common stockholders growth rate is now at -75.19%.
BPMC's revenue has moved up $205,764,000 over the prior 33 months.

The table below shows BPMC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 272.276 -394.986 -717.557
2022-06-30 230.487 -360.692 -701.635
2022-03-31 221.235 -305.601 -650.37
2021-12-31 180.08 -298.653 -644.085
2021-09-30 107.165 -309.338 -411.067
2021-06-30 828.095 408.584 340.152

BPMC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BPMC has a Quality Grade of C, ranking ahead of 33.2% of graded US stocks.
  • BPMC's asset turnover comes in at 0.067 -- ranking 297th of 682 Pharmaceutical Products stocks.
  • OTLC, SGEN, and OCGN are the stocks whose asset turnover ratios are most correlated with BPMC.

The table below shows BPMC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.067 0.871 -0.440
2021-06-30 0.512 0.992 0.352
2021-03-31 0.566 0.999 0.382
2020-12-31 0.634 0.999 0.411
2020-09-30 0.812 1.000 0.485
2020-06-30 0.095 0.998 -0.729

BPMC Price Target

For more insight on analysts targets of BPMC, see our BPMC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $119.69 Average Broker Recommendation 1.47 (Moderate Buy)

Blueprint Medicines Corporation (BPMC) Company Bio

Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.

BPMC Latest News Stream

Event/Time News Detail
Loading, please wait...

BPMC Latest Social Stream

Loading social stream, please wait...

View Full BPMC Social Stream

Latest BPMC News From Around the Web

Below are the latest news stories about BLUEPRINT MEDICINES CORP that investors may wish to consider to help them evaluate BPMC as an investment opportunity.

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective December 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 2,503 shares of its common stock and an aggregate of 1,251 restricted stock units (RSUs) to two new employees under Blueprint Medicines' 2020 Inducement Plan.

Yahoo | December 4, 2023

Why Is Glaxo (GSK) Up 5.3% Since Last Earnings Report?

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 1, 2023

Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | November 30, 2023

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report?

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | November 29, 2023

Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 5, 2023 at 11:00 a.m. ET.

Yahoo | November 28, 2023

Read More 'BPMC' Stories Here

BPMC Price Returns

1-mo 19.47%
3-mo 35.64%
6-mo 23.86%
1-year 54.58%
3-year -31.26%
5-year 26.01%
YTD 65.30%
2022 -59.10%
2021 -4.49%
2020 40.00%
2019 48.60%
2018 -28.51%

Continue Researching BPMC

Want to see what other sources are saying about Blueprint Medicines Corp's financials and stock price? Try the links below:

Blueprint Medicines Corp (BPMC) Stock Price | Nasdaq
Blueprint Medicines Corp (BPMC) Stock Quote, History and News - Yahoo Finance
Blueprint Medicines Corp (BPMC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!